Model | Independent variable | Prevalence (%) | OR (95% CI) | P value | AROC | |
---|---|---|---|---|---|---|
Individual components | ||||||
1 | Elevated waist circumference | 31.1 | 6.13 (4.44–8.45) | <0.0001 | 0.74 | |
2 | Elevated triglyceride | 30.6 | 1.68 (1.23–2.25) | 0.0004 | 0.61 | |
3 | Low HDL | 50.5 | 2.60 (1.97–3.44) | <0.0001 | 0.66 | |
4 | Elevated blood pressure | 46.5 | 2.37 (1.78–3.14) | <0.0001 | 0.65 | |
5 | IFG | 15.0 | 2.23 (1.69–2.94) | <0.0001 | 0.64 | |
6 | CRP >3 mg/l | 29.8 | 2.49 (1.84–3.36) | <0.0001 | 0.65 | |
7 | ALT (upper quartile) | 26.5 | 3.00 (2.19–4.12) | <0.0001 | 0.66 | |
Waist and ALT | ||||||
8 | Elevated waist circumference | 5.73 (4.14–7.95) | <0.0001 | |||
ALT (upper quartile) | 2.64 (1.88–3.70) | <0.0001 | 0.76* | |||
Hypertriglyceridemic waist models | ||||||
9 | Hypertriglyceridemic waist | 17.9 | 2.73 (1.94–3.84) | <0.0001 | 0.64 | |
10 | Hypertriglyceridemic waist | 2.56 (1.80–3.63) | <0.0001 | |||
CRP >3 mg/l | 2.37 (1.74–3.21) | <0.0001 | 0.68† | |||
11 | Hypertriglyceridemic waist | 2.55 (1.79–3.62) | <0.0001 | |||
ALT (upper quartile) | 2.88 (2.08–3.97) | <0.0001 | 0.68†† | |||
12 | Hypertriglyceridemic waist | 2.37 (1.65–3.39) | <0.0001 | |||
CRP >3 mg/l | 2.42 (1.77–3.31) | <0.0001 | ||||
ALT (upper quartile) | 2.94 (2.12–4.09) | <0.0001 | 0.72††† | |||
EWET models | ||||||
13 | EWET | 23.1 | 4.61 (3.32–6.41) | <0.0001 | 0.69 | |
14 | EWET | 4.15 (2.97–5.80) | <0.0001 | |||
CRP >3 mg/l | 2.09 (1.52–2.86) | <0.0001 | 0.72‡ | |||
15 | EWET | 4.27 (3.05–5.97) | <0.0001 | |||
ALT (upper quartile) | 2.71 (1.95–3.78) | <0.0001 | 0.72‡‡ | |||
16 | EWET | 2.15 (1.56–2.96) | <0.0001 | |||
CRP >3 mg/l | 2.77 (1.98–3.88) | <0.0001 | ||||
ALT (upper quartile) | 3.80 (2.70–5.35) | <0.0001 | 0.74‡‡‡ | |||
TG-to-HDL ratio models | ||||||
17 | TG/HDL (≥3) | 40.7 | 2.44 (1.84–3.23) | <0.0001 | 0.65 | |
18 | TG/HDL (≥3) | 2.37 (1.78–3.16) | <0.0001 | |||
CRP >3 mg/l | 2.45 (1.80–3.33) | <0.0001 | 0.69§ | |||
19 | TG/HDL (≥3) | 2.29 (1.72–3.05) | <0.0001 | |||
ALT (upper quartile) | 2.83 (2.05–3.91) | <0.0001 | 0.69§§ | |||
20 | TG/HDL (≥3) | 2.22 (1.66–2.98) | <0.0001 | |||
CRP >3 mg/l | 2.51 (1.84–3.44) | <0.0001 | ||||
ALT (upper quartile) | 2.90 (2.08–4.03) | <0.0001 | 0.72§§§ | |||
HOMA-IR models | ||||||
21 | HOMA-IR (upper quartile) | 32.7 | 11.72 (8.45–16.23) | <0.0001 | 0.79 | |
22 | HOMA-IR (upper quartile) | 11.01 (7.92–15.30) | <0.0001 | |||
CRP >3 mg/l | 1.99 (1.40–2.82) | 0.0001 | 0.81¶ | |||
23 | HOMA-IR (upper quartile) | 10.46 (7.51–14.58) | <0.0001 | |||
ALT (upper quartile) | 1.84 (1.27–2.66) | 0.0013 | 0.79¶¶ | |||
24 | HOMA-IR (upper quartile) | 9.75 (6.98–13.63) | <0.0001 | |||
CRP >3 mg/l | 2.04 (1.44–2.90) | <0.0001 | ||||
ALT (upper quartile) | 1.90 (1.31–2.77) | 0.0008 | 0.81¶¶¶ | |||
Metabolic syndrome models | ||||||
25 | NCEP metabolic syndrome | 26.8 | 4.44 (3.25–6.07) | <0.0001 | 0.70 | |
26 | NCEP metabolic syndrome | 3.99 (2.90–5.48) | <0.0001 | |||
CRP >3 mg/l | 2.04 (1.48–2.79) | <0.0001 | 0.72# | |||
27 | NCEP metabolic syndrome | 4.01 (2.91–5.51) | <0.0001 | |||
ALT (upper quartile) | 2.55 (1.83–3.56) | <0.0001 | 0.73## | |||
28 | NCEP metabolic syndrome | 3.56 (2.57–4.93) | <0.0001 | |||
CRP >3 mg/l | 2.11 (1.53–2.91) | <0.0001 | ||||
ALT (upper quartile) | 2.62 (1.87–3.67) | <0.0001 | 0.75### | |||
29 | NCEP metabolic syndrome | 2.01 (1.38–2.91) | 0.0002 | |||
CRP >3 mg/l | 1.87 (1.31–2.67) | 0.0006 | ||||
HOMA-IR (upper quartile) | 8.17 (5.78–11.54) | <0.0001 | ||||
ALT (upper quartile) | 1.80 (1.23–2.64) | 0.0024 | 0.82#### |
Logistic regression models were adjusted for age, sex, and ethnicity; rows 1–5 are NCEP-defined traits. The dependent variable is the lowest quartile of S_{i} measured by an FSIVGTT. Models 8, 10–12, 14–16, 18–20, 22–24, and 26–29 show multivariate results with ORs for risk definitions adjusted for other variables in the model. Independent variables are elevated waist (waist circumference >102 cm [men] or >88 cm [women]), elevated triglyceride level (triglycerides ≥150 mg/dl), low HDL (HDL cholesterol <40 mg/dl [men] or <50 mg/dl [women]), elevated blood pressure (blood pressure ≥130/≥85 mmHg), IFG (fasting glucose ≥110 mg/dl), ALT (upper quartile [≥23 units/l]), hypertriglyceridemic waist (waist circumference ≥90 cm [men] or ≥80 cm [women] and triglycerides ≥175 mg/dl), EWET, (waist circumference ≥95 cm [men] or ≥88 cm [women] and triglycerides ≥128 mg/dl); HOMA [(insulin × glucose [millimoles per liter])/22.5, with elevated HOMA ≥4.02], and NCEP metabolic syndrome (≥3 of the disorders listed in the first 5 rows of this table). P values for AROC comparisons:
↵* Adding ALT to waist circumference, P = 0.01;
↵† Adding CRP to hypertriglyceridemic waist, P = 0.001;
↵†† Adding ALT to hypertriglyceridemic waist, P = 0.003;
↵††† Adding CRP and ALT to hypertriglyceridemic waist, P < 0.0001;
↵‡ Adding CRP to EWET, P = 0.002;
↵‡‡ Adding ALT to EWET, P = 0.01;
↵‡‡‡ Adding CRP and ALT to EWET, P < 0.0001;
↵§ Adding CRP to elevated triglycerides-to-HDL (Tg/HDL) ratio, P = 0.004;
↵§§ Adding ALT to elevated triglycerides-to-HDL ratio, P = 0.005;
↵§§§ Adding CRP and ALT to elevated triglycerides-to-HDL ratio, P < 0.0001;
↵¶ Adding CRP to HOMA-IR, P = 0.02;
↵¶¶ Adding ALT to HOMA-IR, P = 0.21;
↵¶¶¶ Adding CRP and ALT to HOMA-IR, P = 0.004;
↵# Adding CRP to NCEP metabolic syndrome, P = 0.03;
↵## Adding ALT to NCEP metabolic syndrome, P = 0.005;
↵### Adding CRP and ALT to NCEP metabolic syndrome, P < 0.0001;
↵#### Adding CRP, ALT, and HOMA-IR to NCEP metabolic syndrome, P < 0.0001.